(Massachusetts Institute of Technology) MIT researchers are employing novel machine-learning techniques to improve the quality of life for patients by reducing toxic chemotherapy and radiotherapy dosing for glioblastoma, the most aggressive form of brain cancer.

Related Links:

(Natural News) Chemotherapy is depressing enough, but a drug used in the procedure may heighten it and make it worse, according to a study by researchers from King’s College London. Depression is considered one of the least recognizable symptoms of cancer since the condition is commonly attributed to the shock of the patient upon hearing…

Source: NaturalNews.comCategory: Consumer Health News Source Type: news

Conclusion: Significantly more patients had unilateral rather than bilateral regional differences (both increases and decreases) in 18F-FDG uptake in the brain pre-and post PCI. This suggests that differences in unilateral distribution are related to functional changes, since direct toxicity alone from PCI and chemotherapy would be symmetric. The frontal region was the most commonly affected, suggesting a potential contributing etiology for cognitive impairment and decreased executive function after therapy.
PMID: 30076247 [PubMed – as supplied by publisher]

Authors: Jiang L, Chen S, Zhao D, Yan J, Chen J, Yang C, Zheng G
Abstract
Glioma is the most common type of malignant intracranial tumor in adults and is associated with the highest mortality rate. Although surgery, radiotherapy, chemotherapy and other treatment methods have progressed, the median survival of patients with glioma is only 14‑15 months. Glioma cells are able to penetrate along blood vessels and invade into the surrounding normal brain tissue so that an overall resection of the tumor cannot be performed. In the process of metastasis, the resistance of cancer cells to anoikis has an important ro…

Abstract
BACKGROUND: The purpose of the current study is to investigate the impact of baseline characteristics on the outcomes of extensive-stage small cell lung cancer (SCLC) patients recruited into a clinical trial.
METHODS: This is a secondary analysis of the control arm (etoposide/carboplatin arm) of the “NCT00363415″ study which is a phase III study conducted between 2006 and 2007. Univariate analysis of factors affecting overall and progression-free survival was conducted through Cox regression analysis [including age, race, gender, ECOG performance score, body mass index, LDH, number of meta…

Source: Clinical Lung CancerCategory: Cancer & Oncology Authors: Tags: Clin Respir J Source Type: research

ConclusionsAtezolizumab was safe and well tolerated in this group of patients with recurrent glioblastoma. Our preliminary findings suggest that biomarkers, including peripheral CD4+  T cells and hypermutated tumor status, may help guide selection of patients with recurrent glioblastoma who might receive most benefit from atezolizumab therapy, supporting further atezolizumab combination studies in glioblastoma.

CONCLUSIONS: Clinical symptoms and cancer characteristics were correlated with the development of CNSm. Specific risk and protective factors were identified. Among BC patients with neurological symptoms, CNSm should always be considered, especially in patients with certain oncological and clinical features.
PMID: 30086430 [PubMed – as supplied by publisher]

Source: Clinical Genitourinary CancerCategory: Cancer & Oncology Authors: Tags: Clin Neurol Neurosurg Source Type: research

Abstract
Cancer chemotherapy is mainly based on the use of cytotoxic compounds that often affect other tissues, generating serious side effects which deteriorate the quality of life of patients. Recent advancements in targeted drug delivery systems offer opportunities to improve the efficiency of chemotherapy, by the use of smaller drug doses with reduced side effects. In the gene therapy approach, this consists in improving the transformation potential of the gene delivery system. Interestingly, these systems further provide good platforms for the delivery of hydrophobic and low-bioavailability compounds, while f…

Source: Biotechnology AdvancesCategory: Biotechnology Authors: Tags: Biotechnol Adv Source Type: research

(Natural News) Roughly sixty percent of all brain cancer are gliomas, a tumor that starts in the glial cells of the brain or the spine. There are many different grades of gliomas; each describing a variance in growth potential and aggressiveness. Regardless, conventional therapies involving radiation and chemotherapy drugs have been shown to be inconsistent…

Source: NaturalNews.comCategory: Consumer Health News Source Type: news

(University of Illinois at Chicago) Researchers at the University of Illinois at Chicago have demonstrated that magnetic nanoparticles can be used to ferry chemotherapy drugs into the spinal cord to treat hard-to-reach spinal tumors in an animal model. The unique delivery system represents a novel way to target chemotherapy drugs to spinal cancer cells, which are hard to reach because the drugs must cross the blood-brain barrier.

Epithelial-to-mesenchymal transition (EMT) plays an important role in invasion and metastasis of various cancers including gliomas. EMT has also been linked to cancer stem cells and resistance to chemotherapy. An initial in-silico data mining in a published ependymoma (EPN) patient series (GSE21687) revealed upregulation of EMT-Transcription factors (EMT-TFs) in tumor samples. Further, quantitative real-time polymerase chain reaction (q-RT-PCR) based gene expression analysis of EMT-TFs in 96 EPNs showed significant up-regulation of SNAI1, SNAI2, ZEB1, and TWIST1 as compared to normal brain, associated with upregulation of …

Source: Human PathologyCategory: Pathology Authors: Tags: Original contribution Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image